BSPM [Biostar Pharmaceuticals,] 8-K: FORM 8-K CURRENT REPORT Date of Report (Date

[FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): November 22, 2013 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-03T10:34:32+00:00 November 27th, 2013|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: FORM 8-K CURRENT REPORTte of Report (Date of

[FORM 8-K CURRENT REPORTte of Report (Date of earliest event reported):November 22, 2013 BIOSTAR PHARMACEUTICALS, Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer oforporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, Peoples Republic of China 712046 86-029-33686638 N/A (Former name or formerdress, if changed since last report)]

By | 2016-02-07T15:02:50+00:00 November 27th, 2013|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[FORM 8-K CURRENT REPORTte of Report (Date of earliest event reported):November 22, 2013 BIOSTAR PHARMACEUTICALS, Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer oforporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, Peoples Republic of China 712046 86-029-33686638 N/A (Former name or formerdress, if changed since last report)]

By | 2016-02-07T15:01:54+00:00 November 27th, 2013|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Reports First Quarter Fiscal Year 2014 Financial

[TPI Reports First Quarter Fiscal Year 2014 Financial Results November 15, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter fiscal year 2014. First Quarter Fiscal Year 2014 Ended September 30, 2013 Financial Highlights:] [Tianyin Pharmaceutical Inc. First Quarter Fiscal Year 2014 Financial Results Conference Call November 15, 2013 Operator. I will now turn the presentation over to James Tong. Please go ahead, Mr. Tong. James Tong Below are the financial highlights for the first quarter of fiscal year 2014 ended September 30, 2013: Revenue totaled $14.8 million, compared with $16.0 million in the] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 15, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-27T17:49:02+00:00 November 20th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule BSPM XIANYANG, China, Nov. 13, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. ( Ronghua Wang, Biostar's Chairman, commenting on the announcement, stated: "We strongly believe that regaining compliance with NASDAQ's continued listing requirements is an important achievement for the Company. Having resolved this issue, we can continue focusing on]

By | 2016-03-03T10:39:41+00:00 November 14th, 2013|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00

[Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule BSPM XIANYANG, China, Nov. 13, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. ( Ronghua Wang, Biostar's Chairman, commenting on the announcement, stated: "We strongly believe that regaining compliance with NASDAQ's continued listing requirements is an important achievement for the Company. Having resolved this issue, we can continue focusing on]

By | 2016-03-03T10:41:15+00:00 November 14th, 2013|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x September 30, 2013 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC Nevada 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 14, 2013 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321093013.htm]

By | 2016-03-03T16:35:28+00:00 November 14th, 2013|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x September 30, 2013

[FORM 10-Q (Mark One) x September 30, 2013 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC Nevada 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 14, 2013 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321093013.htm]

By | 2016-03-03T16:36:22+00:00 November 14th, 2013|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments
Read More
Skip to toolbar